Mineralys Therapeutics (MLYS) Set to Announce Quarterly Earnings on Monday

Mineralys Therapeutics (NASDAQ:MLYS) is scheduled to be posting its quarterly earnings results after the market closes on Monday, November 11th. Analysts expect Mineralys Therapeutics to post earnings of ($0.83) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same quarter in the prior year, the business earned ($0.31) EPS. On average, analysts expect Mineralys Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Mineralys Therapeutics Stock Down 0.8 %

Shares of Mineralys Therapeutics stock opened at $14.04 on Friday. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $16.91. The stock has a market cap of $698.21 million, a PE ratio of -5.18 and a beta of 1.71. The business has a fifty day simple moving average of $12.90 and a 200-day simple moving average of $12.61.

Insider Buying and Selling at Mineralys Therapeutics

In other news, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Jon Congleton sold 15,271 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the sale, the chief executive officer now directly owns 895,941 shares of the company’s stock, valued at $12,113,122.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the sale, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,510 shares of company stock valued at $735,431 in the last quarter. Company insiders own 33.24% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research note on Thursday, October 31st.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.